Literature DB >> 8188384

Protection of gerbils from amebic liver abscess by immunization with a recombinant protein derived from the 170-kilodalton surface adhesin of Entamoeba histolytica.

T Zhang1, S L Stanley.   

Abstract

The protozoan parasite Entamoeba histolytica causes extensive morbidity and mortality worldwide through intestinal infection and amebic liver abscess. Here we show that vaccination of gerbils, a standard model for amebic liver abscess, with recombinant proteins derived from the 170-kDa galactose-binding adhesin of E. histolytica and the serine-rich E. histolytica protein or a combination of the two recombinant antigens provides excellent protection against subsequent hepatic challenge with virulent E. histolytica trophozoites.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8188384      PMCID: PMC186551          DOI: 10.1128/iai.62.6.2605-2608.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Vaccination against hepatic amebiasis in hamsters.

Authors:  E Ghadirian; E Meerovitch
Journal:  J Parasitol       Date:  1978-08       Impact factor: 1.276

2.  [Induction of protective antiamebic immunity in hamsters with heterologous antigens].

Authors:  J M Jiménez Cardoso; E Jiménez; M de Jesús Bernal; J Kumate
Journal:  Rev Invest Clin       Date:  1989 Apr-Jun       Impact factor: 1.451

3.  Elicitation of protective immunity to Entamoeba histolytica--an experimental study.

Authors:  P C Nain; V K Vinayak
Journal:  Immunol Cell Biol       Date:  1987-06       Impact factor: 5.126

4.  Human T-lymphocyte proliferation, lymphokine production, and amebicidal activity elicited by the galactose-inhibitable adherence protein of Entamoeba histolytica.

Authors:  D C Schain; R A Salata; J I Ravdin
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

Review 5.  Entamoeba histolytica: from adherence to enteropathy.

Authors:  J I Ravdin
Journal:  J Infect Dis       Date:  1989-03       Impact factor: 5.226

6.  Vaccination of rabbits against Entamoeba histolytica with aqueous suspensions of trehalose-dimycolate as the adjuvant.

Authors:  A Sharma; A Haq; S Ahmad; E Lederer
Journal:  Infect Immun       Date:  1985-06       Impact factor: 3.441

7.  Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase.

Authors:  K L Guan; J E Dixon
Journal:  Anal Biochem       Date:  1991-02-01       Impact factor: 3.365

8.  Protection of gerbils from amebic liver abscess by immunization with the galactose-specific adherence lectin of Entamoeba histolytica.

Authors:  W A Petri; J I Ravdin
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

9.  Isolation of the galactose-binding lectin that mediates the in vitro adherence of Entamoeba histolytica.

Authors:  W A Petri; R D Smith; P H Schlesinger; C F Murphy; J I Ravdin
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

10.  Protection of gerbils from amebic liver abscess by immunization with a recombinant Entamoeba histolytica antigen.

Authors:  T Zhang; P R Cieslak; S L Stanley
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

View more
  18 in total

1.  The cysteine-rich region of the Entamoeba histolytica adherence lectin (170-kilodalton subunit) is sufficient for high-affinity Gal/GalNAc-specific binding in vitro.

Authors:  D R Pillai; P S Wan; Y C Yau; J I Ravdin; K C Kain
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

2.  CpG-oligodeoxynucleotide is a potent adjuvant with an Entamoeba histolytica Gal-inhibitable lectin vaccine against amoebic liver abscess in gerbils.

Authors:  Catherine P A Ivory; Kathy Keller; Kris Chadee
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon.

Authors:  Xiaoti Guo; Lisa Barroso; Steven M Becker; David M Lyerly; Thomas S Vedvick; Steven G Reed; William A Petri; Eric R Houpt
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

Review 4.  Progress towards development of a vaccine for amebiasis.

Authors:  S L Stanley
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

Review 5.  The future for vaccine development against Entamoeba histolytica.

Authors:  Jeanie Quach; Joëlle St-Pierre; Kris Chadee
Journal:  Hum Vaccin Immunother       Date:  2014-02-06       Impact factor: 3.452

6.  The tumor necrosis factor alpha-stimulating region of galactose-inhibitable lectin of Entamoeba histolytica activates gamma interferon-primed macrophages for amebicidal activity mediated by nitric oxide.

Authors:  R Séguin; B J Mann; K Keller; K Chadee
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

7.  Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice.

Authors:  E T Ryan; J R Butterton; T Zhang; M A Baker; S L Stanley; S B Calderwood
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

8.  Immunization with the Entamoeba histolytica surface metalloprotease EhMSP-1 protects hamsters from amebic liver abscess.

Authors:  Eduardo C Roncolato; José E Teixeira; José E Barbosa; Leandra N Zambelli Ramalho; Christopher D Huston
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

9.  Oral immunization with the dodecapeptide repeat of the serine-rich Entamoeba histolytica protein (SREHP) fused to the cholera toxin B subunit induces a mucosal and systemic anti-SREHP antibody response.

Authors:  T Zhang; E Li; S L Stanley
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

10.  VH3 gene usage in neutralizing human antibodies specific for the Entamoeba histolytica Gal/GalNAc lectin heavy subunit.

Authors:  Hiroshi Tachibana; Katsuomi Watanabe; Xun-Jia Cheng; Hideo Tsukamoto; Yoshimasa Kaneda; Tsutomu Takeuchi; Seiji Ihara; William A Petri
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.